Watervein Partners raised a 2
billion biotech venture fund. The firmfs first
fund, named Watervein Technology Investment Fund
I, will not only invest into biotechnology,
medical and life science based start-up
ventures, but also will provide them with
thorough hands-on. The main investor in the fund
is Development Bank of Japan, and the remainders
are including Alternative Investment Capital (AI
Capital; a joint co of Mitsubishi Corp. and
Daido Life Insurance), Tokyo Medium and Small
Business Investment Consultation (Tokyo SBIC),
SMBC Capital, Fuso Pharmaceutical Industries,
Mitsubishi Corp. and UFJ Bank. [ news index
]
COPYRIGHT 2004 WATERVEIN PARTNERS ALL RIGHTS
RESERVED.
